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Abstract
Background: To provide doctors with producer-independent information to facilitate choice of
treatment is an important task. The objective of the present study was to evaluate if an e-mail with
a drug information attachment has effects on sales of prescribed drugs and if the design of the
attachment is of importance.
Methods: The Swedish pharmaceutical benefit board found rizatriptan (Maxalt®) 10 mg to be the
most cost-effective triptan. All 119 heads of primary care units in western Sweden were
randomized to receive information concerning this conclusion via (i) e-mail with attachment I, (ii)
e-mail with attachment II or (iii) no information (control). Attachment I was a short one (heading
plus three lines text), whereas attachment II was a long one (heading plus one page text and one
page with tables). The change in percentage rizatriptan of total triptans sold before and after the
intervention (May – July 2004 and May – July 2005, respectively) was compared between the
groups.
Results: Totally 48,229 (2004) and 50,674 (2005) defined daily doses of triptans were prescribed
and sold during May – July in primary care units in the western part of Sweden. The absolute change
in percentage rizatriptan was greater in the intervention groups compared with the control group
2 (25th – 75th percentile: -3 – 7) vs 0 (-7 - 5), P = 0.031). The absolute change in percentage
rizatriptan did not differ between the two attachment groups (P = 0.93).
Conclusion: An e-mail with a drug information attachment may influence sales of prescribed
drugs. No difference between different designs of the attachment could be detected.
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Background
Drugs are keystones in the treatment of patients. Rational
treatment with drugs requires adequate knowledge on
drugs' benefits, risks and cost-effectiveness. The increasing
volume of information related to drugs and prescribing
may make it difficult for an individual primary care doctor
to keep up to date with best practice. Lack of time for read-
ing and evaluating scientific papers in favour of direct
patient work may be one explanation. To consider costs
when prescribing may add an additional difficulty. How-
ever, in a survey, the majority of the doctors stated that
costs of medicines are important and they were willing to
make economic considerations in prescribing [1]. There-
fore, it seems reasonable to provide doctors with pro-
ducer-independent information including cost-
effectiveness to facilitate choice of treatment.
The results of research and development have to be con-
veyed to practicing doctors. Producer-independent infor-
mation on drugs can be provided in different ways. Oral
information combined with reminding notes has been
shown to influence prescription patterns [2] as well as
interactive teleconference [3]. Cochrane reviews indicate
that audit and feedback [4] as well as interactive work-
shops [5] and educational outreach visits [6] can be effec-
tive in improving professional practice. However, these
methods are time-consuming and expensive. Other sup-
plementary methods to convey new knowledge are
needed.
In the western part of Sweden, news concerning drugs is
distributed to the heads of each primary care unit via
attachments in e-mails from the regional department of
health, pharmaceutical unit, with a standard format of the
attachments. The head is instructed to forward the mes-
sage to the employees. To the best of our knowledge, no
reports on effects of e-mails with drug information on
drug sales have been published.
The aims of the present study were to evaluate if these e-
mails with drug information attachments have effects on
sales of prescribed drugs and if the design of the attach-
ment is of importance.
Methods
In Sweden, the pharmaceutical benefits board
(Läkemedelsförmånsnämnden, LFN) decides if a pharma-
ceutical product is to be included in the pharmaceutical
benefits scheme and be reimbursed by the state. Amongst
other things, the decision is based on cost-effectiveness. In
2004, an evaluation of triptans, used for migraine treat-
ment, was presented. Rizatriptan (Maxalt®) 10 mg was
found to be the most cost-effective triptan [7].
Public primary care units in the western Sweden are
directed by totally 119 heads, all of which were included
in the present study. In order to compare the effects of two
drug information alternatives on percentage rizatriptan
sales in an unbiased fashion, the allocation was by rand-
omization. Each head of a primary care unit constituted a
randomization unit and these were arranged in a list, geo-
graphically related units being placed together. A 1:1:1
allocation sequence consisting of randomized permuted
blocks was then applied to this list on the 28th of April
2005, i.e. before the e-mails were sent. A person not
involved in the study and without knowledge about the
study protocol performed the randomization procedure.
The three randomization groups received (i) an e-mail
with attachment I, (ii) an e-mail with attachment II or (iii)
no e-mail at all. The attachments followed the standard
settings of e-mails from the regional department of
health, pharmaceutical unit. Attachment I was a short
message consisting of the heading 'Prescribe Maxalt® 10
mg when a triptan is needed for migraine treatment', fol-
lowed by three lines of text. Attachment II was a long mes-
sage consisting of the same heading as attachment I,
followed by one page of text and one page with three
tables. The name of the attachment was identical to other
drug information attachments from the regional depart-
ment of health, pharmaceutical unit. The attachments can
be supplied from the corresponding author by request.
The e-mails were sent the last work day of April 2005. The
subject of the e-mail was 'to be forwarded to the prescrib-
ers' and in the e-mail the following text was included:
'Information on the LFN review of triptans. To be for-
warded to the prescribers in the primary care unit'. The
primary care units were not informed about the study.
Apoteket AB has monopoly of prescription drug sales in
Sweden. A national prescription register (Xplain) was
established in the late 1990s to improve possibilities for
drug utilization studies. Data on age, sex and residential
area of the patient, as well as information on the pre-
scriber and the drug dispensed (e.g. number of defined
daily doses (DDD) and costs) are routinely gathered when
prescriptions are dispensed at Swedish pharmacies.
Xplain was used for evaluation of effects on sales of pre-
scribed drugs by the e-mail.
Statistics
The percentage rizatriptan of total triptans sold (DDD)
was calculated for each unit in the randomization groups.
By use of Mantel's test [8], comparisons of absolute
change of percentage rizatriptan before and after the inter-
vention (May – July 2004 and May – July 2005, respec-
tively) between the groups were performed. In this case
Mantel's test meant that the comparisons were performed
within subgroups of units all of which belonged to theBMC Clinical Pharmacology 2007, 7:12 http://www.biomedcentral.com/1472-6904/7/12
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same interval of baseline proportion. The results of the
subgroups were pooled to one test for each comparison.
By that technique the influence of the baseline proportion
was eliminated. Values are presented as median (25th –
75th percentile). A P-value < 0.05 was considered signifi-
cant.
Results
Totally 48,229 (2004) and 50,674 (2005) DDD triptans
were sold during May – July in primary care units in the
western part of Sweden. Baseline sold triptans in the pri-
mary care units in the three randomization groups was
(DDD): 377 (244 – 544) (attachment I, n = 40), 333 (197
– 592) (attachment II, n = 40) and 386 (200 – 509) (con-
trol, n = 39). Percentage rizatriptan at baseline and abso-
lute change in percentage rizatriptan after the intervention
in the randomization groups are illustrated in Figure 1.
Percentage rizatriptan before and after the intervention as
well as absolute and relative change is described in Table
1. The absolute change in percentage rizatriptan was
greater in the combined intervention groups compared
with the control group [2 (-3 – 7) vs 0 (-7 - 5), P = 0.031].
The absolute change in percentage rizatriptan did not dif-
fer between the two attachments (P = 0.93).
Discussion
The results of research and development have to be con-
veyed to practicing doctors. Generally, drug information
to primary health care doctors is given by pharmaceutical
sales representatives. It has been shown that frequent vis-
its by representatives are associated with increased pre-
scribing costs [9,10]. To the best of our knowledge, no
information on effects on quality of prescription is avail-
able. Producer-independent information may have an
advantage in this aspect, since the primary aim is not to
sell drugs, but rather to improve health care.
The results of the present study indicate that producer-
independent drug information via an e-mail attachment
may have a modest effect on sales of prescribed drugs. No
difference between different designs of the attachment
could be detected. Thus, e-mails with attachments may be
an alternative or a complement to other interventions, e.g.
education. The difference between prescribing and sales
may be substantial since many prescriptions are not dis-
pensed. Hence, the results of the present study cannot
directly be interpreted as effects on prescription patterns.
In the present study, we do not know to what extent the e-
mail actually reached the target population, the prescrib-
ing doctors, since it was only administered to the heads of
the primary care units. If the forwarding process was not
adequate, the effect of a drug information attachment in
an e-mail on prescription patterns may have been under-
estimated. Moreover, the information in the attachment
may also have reached the prescribing doctors in the con-
trol group. These factors may have influenced the results.
One problem for doctors is the large amount of informa-
tion available and the sparse amount of time to assimilate
the information. The present study does not increase the
doctors' time for reading, but indicates that doctors may
have time to read an e-mail with an attachment from a
trustworthy source and this may have an effect on the pre-
scription.
The present study only allows conclusions regarding
effects on sales of prescribed drugs during the three
months follow-up. The effects of other interventions on
prescription patterns seem to diminish three to four
months after the intervention [2,11]. One advantage with
the 'e-mail attachment intervention' is that it can be
repeated without being costly. However, the results of the
present study only apply to one single message. The effects
of multiple e-mails or repeated e-mails need to be further
explored.
Conclusion
The present study indicates that an e-mail with a drug
information attachment may influence sales of prescribed
drugs. No difference between different designs of the
attachment could be detected. E-mail with attachment
may thus be an alternative to provide doctors with pro-
ducer-independent drug information.
Absolute change in percentage rizatriptan (after intervention  minus baseline) depending on randomization group and base- line percentage Figure 1
Absolute change in percentage rizatriptan (after 
intervention minus baseline) depending on randomi-
zation group and baseline percentage. Regression lines 
are indicated in the figure, broken black line denotes attach-
ment I, solid black line denotes attachment II and solid grey 
line denotes control.
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Table 1: Percentage rizatriptan of prescribed and sold triptans before (May – July 2004) and after (May – July 2005) the intervention 
and absolute change in percentage rizatriptan (after minus before).
Percentage rizatriptan before the 
intervention
Percentage rizatriptan after the 
intervention
Absolute change Relative change P-value
Control 6 (2 – 13) 7 (2 – 11) 0 (-7 - 5) -29 (-69 – 83) -
Attachment I 3 (1 – 10) 8 (3 – 14) 3 (-2 – 8) 42 (-51 – 222) 0.071
Attachment II 7 (1 – 13) 8 (2 – 17) 1 (-4 – 6) -1 (-59 – 70) 0.052
Attachment I + II 5 (1 – 12) 8 (3 – 16) 2 (-3 – 7) 20 (-54 – 140) 0.031
Mantel's test was used for comparison of absolute change vs control. Values are presented as median percentage (25th – 75th percentile).